Evidence map›Paper›PMID 36793437›Full record

ArticleACS medicinal chemistry letters2023

Discovery of Bis-sulfonamides as Novel Inhibitors of Mitochondrial NADH-Quinone Oxidoreductase (Complex I).

Atsuhito Tsuji, Takahiro Masuya, Norihito Arichi, Shinsuke Inuki, Masatoshi Murai, Hideto Miyoshi, Hiroaki Ohno

Open access · greenAbstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Atsuhito TsujiGraduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.
Takahiro MasuyaDivision of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan.ORCID https://orcid.org/0000-0003-4950-0527
Norihito ArichiGraduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.ORCID https://orcid.org/0000-0003-3618-4959
Shinsuke InukiGraduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.ORCID https://orcid.org/0000-0002-7525-1280
Masatoshi MuraiDivision of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan.ORCID https://orcid.org/0000-0001-6601-2854
Hideto MiyoshiDivision of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan.
Hiroaki OhnoGraduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.ORCID https://orcid.org/0000-0002-3246-4809
Kyoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitochondrial oxidative phosphorylation (OXPHOS) is an essential cellular metabolic process that generates ATP. The enzymes involved in OXPHOS are considered to be promising druggable targets. Through screening of an in-house synthetic library with bovine heart submitochondrial particles, we identified a unique symmetric bis-sulfonamide, KPYC01112 (

Identifiers

PMID36793437
PMCPMC9923842
OpenAlexW4317860969

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.